Pancreatic ductal adenocarcinoma
Conditions
Interventions
None listed
Sponsors
Nara Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) a histologically proven diagnosis of adenocarcinoma (Malignant detection on cytology alone is also acceptable) (2) initially diagnosed with resectable pancreatic cancer according to the NCCN Guidelines 2023 Version 1. Resectable pancreatic cancer is defined as not abutting the superior mesenteric artery or celiac artery at initial diagnosis. Contact with the superior mesenteric vein or portal vein does not exceed 180 degrees, and the vessel wall is not irregular. (3) underwent neoadjuvant chemoradiotherapy (4) CA19-9 over 100 U/mL and tumor diameter larger than 20 mm after NACRT
Exclusion criteria
Exclusion criteria: (1) requiring treatment or concurrent active malignancies (2) judged to be not appropriate for participation in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative six-month recurrence rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence-free survival time from the start of the initial treatment Incidence rate of adverse events of systemic chemotherapy Resection rate. Short-term postoperative outcomes (complications, postoperative mortality), patterns of recurrence, and identification of contributing factors to survival time Overall survival time from the start of the initial treatment | — |
Countries
Japan
Contacts
Public ContactTaichi Terai
Nara Medical University Department of Surgery
Outcome results
None listed